

## September 2025 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW			
DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
Tryptyr (acoltremon)	Treatment of the signs and symptoms of dry eye disease (DED)	Non-Formulary	NA
Vanrafia (atrasentan)	Reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) $\geq$ 1.5 g/g.	Non-Formulary	NA
Vykat XR (diazoxide choline)	Treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS)	Non-Formulary	NA
Zelsuvmi (berdazimer)	Topical treatment of molluscum contagiosum (MC) in adults and pediatric patients 1 year of age and older.	Non-Formulary	NA

## September 2025 Pharmacy & Therapeutics Committee Decisions

Avmapki Fakzynja (avutometinib/defactinib) <b>Protected Class</b>	Treatment of adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy	Formulary w/PA	NA
Romvimza (vimseltinib) <b>Protected Class</b>	Treatment of adults with KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC) who have received prior systemic therapy	Formulary w/PA	NA
Gomekli (mirdametinib) <b>Protected Class</b>	Treatment of adult and pediatric patients aged = 2 years with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.	Formulary w/PA	NA
Ibtrozi (taletrectinib) <b>Protected Class</b>	Adults with locally advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC).	Formulary w/PA	NA

**Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 01/1/2026.**

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
<b>Ajovy</b> (fremanezumab) 225 mg/1.5 mL PFS & autoinjector for the preventive treatment of migraine in pediatric patients ≥ 6 years of age weighing ≥ 45 kg - age expansion	Non-Formulary	No change
<b>Sirturo</b> (bedaquiline) 20 mg tablets for multidrug resistant tuberculosis in patients ≥ 2 years weighing ≥ 8 kg - age expansion	Formulary	No change

## September 2025 Pharmacy & Therapeutics Committee Decisions

<p><b>Doptelet</b> (avatrombopag) 10 mg sprinkle capsules &amp; 20 mg tablets for thrombocytopenia in pediatric patients <math>\geq</math> 1 year with persistent or chronic ITP - age expansion</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Otezla</b> (apremilast) 10, 20, &amp; 30 mg tablets for active psoriatic arthritis in pediatric patients <math>\geq</math> 6 years - age expansion</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Biktarvy</b> (bictegravir-emtricitabine-tenofovir alafenamide) 50-200-25 mg &amp; 30-120-15 mg tablets for HIV-1 in adult and pediatric patients weighing <math>\geq</math> 14 kg - indication expansion</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Repatha</b> (evolocumab) 140 mg/mL PFS &amp; autoinjector and 420 mg/3.5 mL on-body infusor to reduce risk of MACE in adults at increased risk and as an adjunct to diet and exercise in adult and pediatric patients <math>\geq</math> 10 years of age with HeFH or HoFH</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Skytrofa</b> (lonapegsomatropin) single-dose vials for adults with growth hormone deficiency</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Leqvio</b> (inclisiran) 284 mg/1.5 mL PFS indicated as an adjunct to diet &amp; exercise to reduce LDL in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia</p>	<p>Non- Formulary</p>	<p>No change</p>

## September 2025 Pharmacy & Therapeutics Committee Decisions

<p><b>Koselugo</b> (selumetinib) 10 &amp; 25 mg capsules and 5 &amp; 7.5 mg oral sprinkle capsules for pediatric patients <math>\geq</math> 1 year of age with neurofibromatosis type 1</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Vonvendi</b> (von Willebrand factor [recombinant]) 650 &amp; 1300-unit IV vials for routine prophylactic use in adults with all types of von Willebrand disease (VWD) and treatment of bleeding episodes and perioperative use in pediatric patients - expanded indications</p>	<p>Non-Formulary</p>	<p>No change</p>
<p><b>Opzelura</b> (ruxolitinib) 1.5% cream for atopic dermatitis in pediatric patients <math>\geq</math> 2 years of age</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Empaveli</b> (pegcetacoplan) 1,080 mg/20 mL SQ vial to reduce proteinuria in C3 glomerulopathy or primary immune-complex glomerulonephritis for relapsed or refractory follicular lymphoma</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Evkeeza</b> (evinacumab) 150 mg/mL IV vials to reduce LDL-C in adults &amp; pediatric patients <math>\geq</math> 1 year with homozygous familial hypercholesterolemia - age expansion</p>	<p>Non- Formulary</p>	<p>No change</p>
<p><b>Libtayo</b> (cemiplimab) 350 mg/7 mL IV vials for adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation</p>	<p>Non-Formulary</p>	<p>No change</p>

## September 2025 Pharmacy & Therapeutics Committee Decisions

<p><b>Tecentriq/Tecentriq Hybreza</b> (atezolizumab ± hyaluronidase) and Zepzelca in combination for extensive-stage small cell lung cancer whose disease has not progressed after first-line induction with atezolizumab ± hyaluronidase, carboplatin, &amp; etoposide</p>	Non-Formulary	No change
<p><b>Uzedy</b> (risperidone) 50, 75, 100, 125, 150, 200, &amp; 250 mg PFS for bipolar I disorder</p>	Non-Formulary	No change
<p><b>Wegovy</b> (semaglutide) 0.25, 0.5, 1, 1.7, &amp; 2.4 mg autoinjectors for noncirrhotic metabolic dysfunction-associated steatohepatitis</p>	Non-Formulary	No change
<p><b>Rybelsus</b> (semaglutide) 1.5, 3, 4, 7, 9, &amp; 14 mg tablets to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes at high risk for these events</p>	Formulary	No change
<p><b>Praluent</b> (alirocumab) 75 &amp; 150 mg autoinjectors to reduce risk of MACE in adults at increased risk and as an adjunct to diet &amp; exercise in patients with HeFH &amp; HoFH</p>	Non-Formulary	No change
<p><b>Simponi</b> (golimumab) 50 &amp; 100 mg injection for pediatric patients weighing ≥ 15 kg with moderate to severely active ulcerative colitis</p>	Non-Formulary	No change

## September 2025 Pharmacy & Therapeutics Committee Decisions

<p><b>Olpruva</b> (sodium phenylbutyrate) 0.5, 1, 2, 3, 4, 5, 6, &amp; 6.67 gram packets for patients <math>\geq 1</math> year of age weighing <math>\geq 7</math> kg with urea cycle disorders</p>	<p>Non-Formulary</p>	<p>No change</p>
<p><b>Xeljanz</b> (tofacitinib) 5 &amp; 10 mg tablets and 1 mg/mL oral solution for active psoriatic arthritis in patients <math>\geq 2</math> years of age who have an inadequate response or intolerance to <math>\geq 1</math> TNF blocker</p>	<p>Formulary</p>	<p>No change</p>
<p><b>Revuforj</b> (revumenib) 25, 110, &amp; 160 mg tablets for relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 (NPM1) mutation in adult &amp; pediatric patients <math>\geq 1</math> year of age with no alternative treatment options</p>	<p>Formulary</p>	<p>No change</p>

NEW GENERICS REVIEW		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
<p>Vuity (<b>pilocarpine</b>) 1.25% ophthalmic solution for presbyopia</p>	<p>A new generic is now available, reducing the price from \$78 per bottle to \$53 per bottle</p>	<p>Non-Formulary</p>
<p>Tracleer (<b>bosentan</b>) 32 mg tablet for oral suspension for pulmonary arterial hypertension</p>	<p>Generic tablet formulations of bosentan have been available since May 2019, though the oral dispersible tablets (ODT) have remained branded until now. A single manufacturer has launched a generic product which provides a 22% cost savings from brand.</p>	<p>Non-Formulary</p>
<p><b>Kirsty</b> (insulin aspart) 100 units/mL pen &amp; vial for glycemic</p>	<p>Kirsty is an interchangeable biosimilar for Novolog from Biocon. It does not</p>	<p>Formulary</p>

## September 2025 Pharmacy & Therapeutics Committee Decisions

control in diabetes	represent the lowest net cost insulin aspart product	
Saxenda ( <b>liraglutide</b> ) 18 mg/3 mL pen-injector for weight loss	A single manufacturer launched a generic alternative for Saxenda at a 15% discount. Five other manufacturers are seeking generic entry and price erosion is anticipated with more generic competition expected in 2026.	Non-Formulary
Adzenys XR ( <b>amphetamine ER</b> ) 3.1, 6.3, 9.4, 12.5, 15.7 & 18.8 mg oral disintegrating tablets for ADHD	An authorized generic equivalent of Adzenys XR launched at a small discount to the brand.	Non-Formulary
Venofer ( <b>iron sucrose</b> ) 20 mg/mL injection for iron deficient anemia in patients with chronic kidney disorder	A generic iron sucrose IV solution has launched, which is a generic for Venofer.	Non-Formulary
Ecoza ( <b>econazole nitrate</b> ) 1% foam for tinea pedis (athlete's foot)	An authorized generic of Ecoza has launched. The new generically named product is 3X more expensive than the brand.	Non-Formulary
Endometrin ( <b>progesterone</b> ) vaginal suppository for early pregnancy support	A generic for Endometrin vaginal suppositories has launched at an approximately 10% discount to the brand. There is only 1 manufacturer that launched a generic product. It is unknown if, or when, additional manufacturers might enter the market.	Non-Formulary
Gralise ( <b>gabapentin</b> ) 450, 750, & 900 mg tablets for postherpetic neuralgia	Additional strengths of Gralise are now available as generic gabapentin. This once daily gabapentin tablet is indicated for postherpetic neuralgia	Non-Formulary

## September 2025 Pharmacy & Therapeutics Committee Decisions

<p>Ravicti (<b>glycerol phenylbutyrate</b>) 1.1 g/mL oral solution for urea cycle disorders</p>	<p>Glycerol phenylbutyrate generic recently launched at approximately 20% discount from brand.</p>	<p>Non-Formulary</p>
<p>Rytary (<b>carbidopa-levodopa</b>) 23.75-95, 36.25-145, 48.75-196, &amp; 61.25-245 mg ER capsules for Parkinson's disease</p>	<p>A new authorized generic of carbidopa-levodopa ER capsules recently launched.</p>	<p>Non-Formulary</p>

New or Expanded Formulations		
DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
<p><b>Dexcom G7</b> 15-day sensor for continuous glucose monitoring</p>	<p>The new 15-day Dexcom G7 sensor, which was approved by the FDA in April for adult patients with all diabetes types, recently launched.</p>	<p>Formulary</p>
<p><b>Brynovin</b> (sitagliptin) 25 mg/mL oral solution for adults with type 2 diabetes</p>	<p>Sitagliptin 25 mg/mL oral solution is now available and indicated for use in adults with type 2 diabetes. Recommended dosing is the same as the previously available tablet formulation at 100 mg once daily with reductions for renal impairment.</p>	<p>Non-Formulary</p>
<p><b>Prezcobix</b> (darunavir-cobicistat) 675-150 mg tablets for HIV-1 in treatment-naïve and treatment-experienced adults and pediatric patients weighing <math>\geq</math> 25 kg indication expansion &amp; new dosage form</p>	<p>A new strength of Prezcobix was recently launched to accommodate pediatric patients weighing between 25 kg and &lt; 40 kg.</p>	<p>Formulary</p>
<p><b>Brukinsa</b> (zanubrutinib) 160 mg tablets for various oncology indications</p>	<p>Previously available as an 80 mg capsule, zanubrutinib is now available in a 160 mg tablet. This new strength allows for dose consolidation,</p>	<p>Formulary</p>

## September 2025 Pharmacy & Therapeutics Committee Decisions

	especially for standard dosing, which is 160 mg twice daily or 320 mg once daily.	
<b>Remodulin</b> (treprostinil) 8 mg/20 mL vials for pulmonary arterial hypertension	A new strength of branded Remodulin (treprostinil) vials for injection has launched.	Non- Formulary
<b>Brekiya</b> (dihydroergotamine) 1 mg/mL autoinjector for migraine & cluster headaches	A new dihydroergotamine formulation launched, now available as a subcutaneous solution autoinjector (Brekiya).	Non- Formulary
<b>Zurnai</b> (nalmefene) 1.5 mg/0.5 mL autoinjector for opioid overdose	A new nalmefene formulation launched as an autoinjector (Zurnai), previously available as a nasal spray (Opvee).	Formulary
<b>Eliquis</b> (apixaban) 0.15 mg sprinkle capsules and 0.5, 1.5 & 2 mg tablet packs for oral suspension for anticoagulation	New dosage forms, including a sprinkle capsule and several strengths of tablets for oral suspension, have launched this month to support the new pediatric VTE indication.	Formulary
<b>Skytrofa</b> (lonapegsomatropin) 0.7, 1.4, 1.8, 2.1, & 2.5 mg SQ inj for growth hormone deficiency	Associated with a new expanded indication, new strengths of lonapegsomatropin launched this month.	Formulary
<b>Phyrago</b> (dasatinib) 20, 50, 70, 100, & 140 mg tablets for Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) & Ph+ acute lymphoblastic leukemia (ALL)	A new formulation of dasatinib, branded as Phyrago, was recently made available and eliminates the need to separate administration from gastric acid-reducing agents such as proton pump inhibitors and H2 receptor antagonists.	Non- Formulary

## September 2025 Pharmacy & Therapeutics Committee Decisions

<p><b>Doptelet</b> (avatrombopag) 10 mg sprinkle capsules for thrombocytopenia in pediatric patients <math>\geq</math> 1 year with persistent or chronic ITP</p>	<p>A new lower strength 10 mg sprinkle capsule to support dosing in patients &lt; 6 years of age.</p>	<p>Non-Formulary</p>
<p><b>Otezla XR</b> (apremilast) 75 mg tablets &amp; initiation pack with transition to 75 mg tablet for psoriatic arthritis, plaque psoriasis, or Behcet's disease</p>	<p>Otezla XR (apremilast) 75 mg tablets launched, providing a once daily dosing option. The 75 mg tablets may be used as an alternative to the twice daily 30 mg immediate-release regimen.</p>	<p>Formulary</p>
<p><b>Zanaflex</b> (tizanidine) 8 mg capsules for spasticity</p>	<p>A new 8 mg strength of tizanidine capsule was recently launched. This 8 mg strength, marketed under the brand name Zanaflex, is substantially higher cost than existing generic strengths.</p>	<p>Non-Formulary</p>
<p><b>Escitalopram 15 mg</b> capsules for major depressive disorder &amp; generalized anxiety disorder</p>	<p>Escitalopram 15 mg capsule has joined existing 5 mg, 10 mg, and 20 mg tablet strengths. While this strength allows for a lower pill burden than taking one 5 mg and 10 mg tablet, it comes at a price premium – approximately \$6/dose vs less than \$0.40/dose for the two existing strengths combined.</p>	<p>Non-Formulary</p>
<p><b>Zoryve</b> (roflumilast) 0.05% cream for atopic dermatitis in children aged 2-5 years of age; AND <b>Zoryve</b> (roflumilast) 0.3% foam for plaque psoriasis of scalp &amp; body &amp; seborrheic dermatitis; AND <b>Zoryve</b> (roflumilast) 0.3%</p>	<p>New strengths of Zoryve released to support pediatric use and new indications</p>	<p>Non-Formulary</p>

## September 2025 Pharmacy & Therapeutics Committee Decisions

cream for plaque psoriasis		
<b>Koselugo</b> (selumetinib) 5 & 7.5 mg oral sprinkle capsules neurofibromatosis type 1	New 5 mg and 7.5 mg selumetinib sprinkle capsules launched to support an age expansion for pediatric patients $\geq$ 1 year of age	Formulary
<b>Krystexxa</b> (pegloticase) 8 mg/50 mL IV vial for chronic gout in adults refractory to conventional therapy	Krystexxa (pegloticase) had a new vial size and strength launch, with an 8 mg/50 mL vial for IV administration joining the previously available 8 mg/mL IV vial.	Non-Formulary
<b>Evexithroid</b> (thyroid) 45 & 75 mg tablets for hypothyroidism	Two new strengths of Evexithroid launched (45 and 75 mg tablets) with similar costs to existing strengths.	Non-Formulary
<b>Vyscoxa</b> (celecoxib) 10 mg/mL oral suspension for arthritis & ankylosing spondylitis	A new celecoxib oral suspension launched. The WAC for a 473 mL bottle of Vyscoxa is \$2,895.49. Generic capsules, which can be opened and added to apple sauce, have MAC pricing (~\$0.15 to ~\$1.10).	Non-Formulary
<b>Tonmya</b> (cyclobenzaprine) 2.8 mg sublingual tablet for fibromyalgia	Tonmya is a sublingual formulation of cyclobenzaprine indicated for the treatment of fibromyalgia in adults. Maintenance dosing costs \$1,860 per month.	Non-Formulary
<b>Beizray</b> (docetaxel-albumin) 80 mg/4 mL IV vials for various oncology indications	Beizray was approved via the 505(b)(2) pathway. As it uses albumin instead of synthetic excipients such as polysorbate-80 or sulfobutyl ether cyclodextrin, the manufacturer believes this will be more tolerable.	Non-Formulary
<b>Keytruda Qlex</b> (pembrolizumab-berahyaluronidase alfa) 165 mg-2,000 units/mL SQ vials for	A new subcutaneous, but still healthcare provider administered, version of Keytruda has launched in	Non-Formulary

## September 2025 Pharmacy & Therapeutics Committee Decisions

various oncology indications	Keytruda Qlex. This allows for easier administration as the new dose form can be given over 1-2 minutes, rather than a 30-minute IV infusion.	
------------------------------	---	--

ADDITIONAL ITEMS REVIEWED	
ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 02/01/2026)	<ul style="list-style-type: none"> <li>Dawnzera</li> <li>Inlexzo</li> <li>Keytruda Qlex</li> <li>Papzimeos</li> </ul>